{"id":1065019,"date":"2012-05-27T15:51:24","date_gmt":"2012-05-27T15:51:24","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/industry-sponsored-cardiovascular-cell-therapies-some-metrics\/"},"modified":"2024-08-18T11:08:43","modified_gmt":"2024-08-18T15:08:43","slug":"industry-sponsored-cardiovascular-cell-therapies-some-metrics","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/regenerative-medicine\/industry-sponsored-cardiovascular-cell-therapies-some-metrics.php","title":{"rendered":"Industry-sponsored cardiovascular cell therapies. Some metrics."},"content":{"rendered":"

Tweet<\/a>

<\/span>
Cell therapies for cardiovascular-related conditions is a closely watched, much studied, oft-discussed, and hotly contested segment of the cell therapy industry.<\/span>

<\/span>
The data to-date are admittedly confusing.  From a clinical perspective, the studies for which we have data have been relatively small involving a mish-mash of indications, endpoints, eligibility criterion, methods and\/or route of administration, as well as the <\/span>time of administration relative to event or disease progression.<\/span>

<\/span>
Further compounding any interpretation of the data, from a technical perspective, is the fact the products have been widely varied in terms of being autologous vs allogeneic, expanded and not, genetically modified and not, from a plethora of different sources, and utilizing a wide variety of cell types from skelatal myoblasts, cardiomyocytes, mesenchymal stromal cells, mononuclear cells, etc. <\/span>

<\/span>
All this makes it extremely difficult to draw any conclusions with respect to what's working and what's not.  We will not attempt to do so.<\/span>

<\/span>
All we do below is attempt to give a snapshot of the industry-sponsored cell therapy trials currently ongoing for cardiovascular-related conditions.  So here it is:<\/span>

<\/span>
Commercial<\/b>:<\/span>
Pharmicell<\/a>'s Heartcelligram<\/a> is the <\/span>only cell therapy to have received regulatory approval for commercial distribution for the treatment of a cardiac-related indication.  Heartcelligram is an autologous cell therapy approved in 2011 by the Korean Food and Drug Administration<\/a> (KFDA) for the treatment of Acute Mycardial Infarction (AMI).  The price is reportedly $19,000 and the trial data behind the approval has not yet been published in a peer-reviewed journal<\/a>.<\/span>

<\/span>
Phase III or II\/III<\/b>:<\/span>
There are currently only 3 active and recruiting cardiac-related, industry-sponsored cell therapy trials.  Interestingly they all involve autologous products, two involve devices, two involve centralized manufacturing, two involve bone marrow cells as a source, two are only in European clinical sites, and two are targeting ischemic-related conditions.<\/span><\/p>